CAJ | 학술논문

目的采用肾包膜下种植方案建立人前列腺癌异种移植动物模型.方法 15只SCID雄鼠按随机表分组法随机分为3组,每组5只.应用组织重组技术,将人前列腺癌新鲜组织和新出生BALB/c雄鼠精囊间质(SVM)在体外重组,显微外科条件下种植于SCID鼠肾包膜下,4周后观察肿瘤种植率并称重、计算体积.检测血清前列腺特异性抗原(PSA)值.用细胞角蛋白(CK)8/18、波形蛋白(vimentin)单克隆抗体特异标记人前列腺上皮和基质成纤维细胞,用P63单克隆抗体标记上皮基底膜证实其是否为前列腺癌组织.另将人前列腺癌新鲜组织单独种植于SCID鼠肾包膜下作为对照.结果 15只SCID鼠78只次组织种植中无一只死亡.4周后,重组种植组成瘤率为100%(39/39),单独种植组为94.1%(37/39),差异无统计学意义(P＞0.05).新生瘤体为实体状、不规则、黄/白色,隆出肾脏表面和(或)嵌入肾实质.重组种植组瘤体生长旺盛,单独种植组瘤体较为平坦,肿瘤大小及重量在两组间差异有统计学意义[(9.7±3.1)mm3比(6.8±2.0)mm3;(12.1±3.6)μg比(8.2±2.2)μg,均P＜0.01].重组种植组血清PSA值高于单独种植组,但两组间差异无统计学意义(P＞0.05).CK8/18、vimentin单抗标记证实新生瘤体为人源性前列腺组织,P63单抗标记显示上皮基底膜消失证实为前列腺癌.结论肾包膜下种植可高效率建立人前列腺癌异种移植动物模型.本模型含有肿瘤基质成分,可为体内研究前列腺癌发病和病程演变中间质-上皮细胞相互作用提供技术平台.
목적 채용신포막하충식방안건립인전렬선암이충이식동물모형.방법 15지SCID웅서안수궤표분조법수궤분위3조,매조5지.응용조직중조기술,장인전렬선암신선조직화신출생BALB/c웅서정낭간질(SVM)재체외중조,현미외과조건하충식우SCID서신포막하,4주후관찰종류충식솔병칭중、계산체적.검측혈청전렬선특이성항원(PSA)치.용세포각단백(CK)8/18、파형단백(vimentin)단극륭항체특이표기인전렬선상피화기질성섬유세포,용P63단극륭항체표기상피기저막증실기시부위전렬선암조직.령장인전렬선암신선조직단독충식우SCID서신포막하작위대조.결과 15지SCID서78지차조직충식중무일지사망.4주후,중조충식조성류솔위100%(39/39),단독충식조위94.1%(37/39),차이무통계학의의(P＞0.05).신생류체위실체상、불규칙、황/백색,륭출신장표면화(혹)감입신실질.중조충식조류체생장왕성,단독충식조류체교위평탄,종류대소급중량재량조간차이유통계학의의[(9.7±3.1)mm3비(6.8±2.0)mm3;(12.1±3.6)μg비(8.2±2.2)μg,균P＜0.01].중조충식조혈청PSA치고우단독충식조,단량조간차이무통계학의의(P＞0.05).CK8/18、vimentin단항표기증실신생류체위인원성전렬선조직,P63단항표기현시상피기저막소실증실위전렬선암.결론 신포막하충식가고효솔건립인전렬선암이충이식동물모형.본모형함유종류기질성분,가위체내연구전렬선암발병화병정연변중간질-상피세포상호작용제공기술평태.
Objective To establish the murine xenograft model of human prostate cancer by grafting tumor tissues beneath the renal capsule of intact male athymic mouse. Methods Fifteen SCID mice were randomly divided into 3 groups ( n = 5 each ). Tissue recombinants were prepared in vitro with newborn BALB/c murine seminal vesicle mesenchyme (SVM) and surgical isolated human prostate cancer tissues by using recombination technique and then grafted beneath the renal capsule of intact male athymic mouse. At Week 4 after initial implantation, grafts were harvested and tumor sizes calculated. The expressions of human specific markers CK8/18 and vimentin were evaluated by immunohistochemistry to identify the human prostatic origin in grafts. P63 protein, a basal cell marker, was detected in prostate basal membrane to identify whether it was benign or malignant tissue. And the study control was prepared by implanting prostate cancer tissues alone under the renal capsule in SCID mouse. Results Of all 78 implantation cases in 15 mice, the tumor-forming rates were 100% (39/39)and 94. 1% (37/39)respectively in the recombination and prostate cancer alone grafting groups. The recombination group was shown to be more efficient in terms of tumor size and weight in comparison with the prostate cancer alone group [ ( 9. 7 +- 3. 1 ) vs ( 6. 8 +- 2. 0) mm3, (12. 1 +-3. 6) vs (8. 2 +-2. 2) (u,)g, P <0. 01 ]. There was no difference in serum PSA level between two groups. Grafts were confirmed as human prostate cancer tissues with the expressions of CK8/18 and vimentin. No expression of P63 was detected. Conclusion The xenograft murine model of human prostate cancer is successfully established. It contains stroma components and is particularly suitable for studying the interaction of stroma and epithelia in the in vivo progression of prostate cancer.